Synthesis and Characterization of Novel Quinazoline Type Inhibitors for Mutant and Wild-Type EGFR and RICK Kinases

REFERENCES

• Heymach J V, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small lung canser. Clin Cancer Res 2006; 12: 4441s–4445s
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Tortora G. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: Understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 2003; 39: 1348–1354
   PubMed Web of Science ®Google Scholar
• Keri G, Szekelyhidi Z, Banhegyi P, Varga Z, Hegymegi-Barakonyi B, Szantai-Kis C, Hafenbradl D, Klebl B, Muller G, Ullrich A, Eros D, Horvath Z, Greff Z, Marosfalvi J, Pato J, Szabadkai I, Szilagyi I, Szegedi Z, Varga I, Waczek F, Orfi L. Drug discovery in the kinase inhibitory field using the Nested Chemical Library™ Technology. Assay Drug Dev Technol 2005; 3: 543–551
   PubMed Web of Science ®Google Scholar
• Stamos J, Sliwkowski M X, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002; 277: 46265–46272
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J-Y, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong R-P, Baselga J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237–2246
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Chachoua A, Hammond L A, Rowinsky E K, Huberman M, Karp D, Rigas J, Clark G M, Santabarbara P, Bonomi P. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22: 3238–3247
   PubMed Web of Science ®Google Scholar
• Lynch T J, Bell D W, Sordella R, Gurubhagavatula S, Okimoto R A, Brannigan B W, Harris P L, Haserlat S M, Supko J G, Haluska F G, Louis D N, Christiani D C, Settleman J, Haber D A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129–2139
   PubMed Web of Science ®Google Scholar
• Sordella R, Bell D W, Haber D A, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305: 1163–1167
   PubMed Web of Science ®Google Scholar
• Kosaka T, Yatabe Y, Hideki Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res 2004; 64: 8919–8923
   PubMed Web of Science ®Google Scholar
• Pao W, Miller V A, Politi K A, Riely G J, Somwar R, Zakowski M F, Kris M G, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PloS Med 2005; 2: 0225–0235
   Web of Science ®Google Scholar
• Varkondi E, Pinter F, Robert K, Schwab R, Breza N, Orfi L, Keri G, Petak I. Biochemical assay based selectivity profiling of clinically relevant kinase inhibitors on mutant forms of EGF receptor. J Recept Sig Transd 2008; 28: 295–306
   Web of Science ®Google Scholar
• Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, Muller S, Klebl B, Cotton M, Keri G, Wissing J, Daub H. Cellular targets of Gefitinib. Cancer Res 2005; 65: 379–382
   PubMed Web of Science ®Google Scholar
• Herget T, Freitag M, Morbitzer M, Kupfer R, Stamminger T, Marschall M. Novel chemical class of pUL97 protein kinase-specific inhibitors with strong anticytomegaloviral activity. Antimicrob Agents Chemother 2004; 48: 4154–4162
   PubMed Web of Science ®Google Scholar
• Niementowski S.v. J Prak Chem 1895; 51: 566
   Google Scholar
• Barker A J, Gibson K H, Grundy W, Godfrey A A, Barlow J J, Healy M P, Woodburn J R, Ashton S E, Curry B J, Scarlett L, Henthorn L, Richards L. Studies leading to the identification of ZD1839 (Iressa™): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001; 11: 1911–1914
   PubMed Web of Science ®Google Scholar
• Wang W-C, Iseki E, Imamiya K. Preparation of quinazoline derivative as intermediates for antitumor agent. JP 2002293773, 2002
   Google Scholar
• Godl K, Wissing J, Kurtenbach A, Habenberger P, Blencke S, Gutbrod H, Salassidis K, Stein-Gerlach M, Missio A, Cotten M, Daub H. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci USA 2003; 100: 15434–15439
   PubMed Web of Science ®Google Scholar
• Marschall M, Stein-Gerlach M, Freitag M, Kupfer R, van den Bogaard M, Stamminger T. Inhibitors of human cytomegalovirus replication drastically reduce the activity of the viral protein kinase pUL97. J Gen Virol 2001; 82: 1439–1451
   Google Scholar
• Herget T. Phenyl(quinazolinyl)amines as UL 97-kinase inhibitors for the treatment of human cytomegaloviral and other herpesviral infections. WO 2005040125, 2005
   Google Scholar
• Eros D, Kovesdi I, Orfi L, Takacs-Novak K, Acsady G, Keri G. Reliability of logP predictions based on calculated molecular descriptors: A critical review. Curr Med Chem 2002; 9: 1819–1829
   PubMed Web of Science ®Google Scholar
• Eros D, Keri G, Kovesdi I, Szantai-Kis C, Meszaros G, Orfi L. Comparison of predictive ability of water solubility QSPR models generated by MLR, PLS and ANN methods. Mini-Rev Med Chem 2004; 4: 167–177
   PubMed Web of Science ®Google Scholar
• Hollenbach E, Neumann M, Vieth M, Roessner A, Malfertheiner P, Naumann M. Inhibition of p38 MAP kinase- and RICK/NF-kB-signaling suppresses inflammatory bowel disease. FASEB J 2004; 18: 1550–1552
   PubMed Web of Science ®Google Scholar